- Home
- HIT vs ABVC Comparison
HIT vs ABVC Comparison
Compare HIT & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HIT | ABVC |
|---|---|---|
| Founded | 1964 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.8M | 50.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIT | ABVC |
|---|---|---|
| Price | $1.11 | $1.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 164.6K | 57.6K |
| Earning Date | 03-17-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $30,723,490.00 | $797,916.00 |
| Revenue This Year | $67.75 | $735.18 |
| Revenue Next Year | $29.85 | N/A |
| P/E Ratio | $51.06 | ★ N/A |
| Revenue Growth | 55.15 | ★ 56.52 |
| 52 Week Low | $0.51 | $0.40 |
| 52 Week High | $7.59 | $5.48 |
Technical Indicators
Market Signals| Indicator | HIT | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 36.64 | 32.72 |
| Support Level | $0.99 | $1.53 |
| Resistance Level | $1.17 | $1.74 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 17.05 | 22.81 |
Price Performance
Historical ComparisonAbout HIT Health In Tech Inc.
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.